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Abstract
Background: The focus of studies on high-density lipoproteins (HDL) has shifted from HDL-cholesterol (HDL-C) to
HDL function. We recently demonstrated that low USF1 expression in mice and humans associates with high plasma
HDL-C and low triglyceride levels, as well as protection against obesity, insulin resistance, and atherosclerosis. Here, we
studied the impact of USF1 deficiency on HDL functional capacity and macrophage atherogenic functions, including
inflammation, cholesterol efflux, and cholesterol accumulation.
Methods: We used a congenic Usf1 deficient mice in C57Bl/6JRccHsd background and blood samples were collected
to isolate HDL for structural and functional studies. Lentiviral preparations containing the USF1 silencing shRNA
expression vector were used to silence USF1 in human THP-1 and Huh-7 cells. Cholesterol efflux from acetyl-
LDL loaded THP-1 macrophages was measured using HDL and plasma as acceptors. Gene expression analysis
from USF1 silenced peritoneal macrophages was carried out using Affymetrix protocols.
Results: We show that Usf1 deficiency not only increases HDL-C levels in vivo, consistent with elevated ABCA1 protein
expression in hepatic cell lines, but also improves the functional capacity of HDL particles. HDL particles derived from
Usf1 deficient mice remove cholesterol more efficiently from macrophages, attributed to their higher contents of
phospholipids. Furthermore, silencing of USF1 in macrophages enhanced the cholesterol efflux capacity of these
cells. These findings are consistent with reduced inflammatory burden of USF1 deficient macrophages, manifested by
reduced secretion of pro-inflammatory cytokines MCP-1 and IL-1β and protection against inflammation-induced
macrophage cholesterol accumulation in a cell-autonomous manner.
Conclusions: Our findings identify USF1 as a novel factor regulating HDL functionality, showing that USF1
inactivation boosts cholesterol efflux, reduces macrophage inflammation and attenuates macrophage cholesterol
accumulation, linking improved macrophage cholesterol metabolism and inflammatory pathways to the antiatherogenic
function of USF1 deficiency.
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Introduction
Low level of high-density lipoprotein cholesterol (HDL-C)
is a major independent risk factor for atherosclerotic car-
diovascular disease [1]. However, recent studies have
shown that raising HDL-cholesterol (HDL-C) levels by
pharmacological agents does not translate into better clin-
ical outcomes. The HDL-C raising agent niacin and CETP
inhibitors, when administered on top of statins, both failed
to reduce cardiovascular events despite markedly increas-
ing HDL-C levels [2–4]. Furthermore, Mendelian
randomization studies using complex genetics have
shown that variants associated exclusively with high
HDL-cholesterol levels, are not associated with reduc-
tion in cardiovascular outcomes [5]. These findings
suggest that HDL-C is unlikely to be causally related
to cardiovascular disease. Thus, research efforts have
shifted from HDL-C levels to HDL function.
The canonical functions of HDL particles include their
anti-inflammatory and antioxidative properties, as well
as their role in the initiation of reverse cholesterol trans-
port [6]. Cholesterol efflux from cells to circulation is
the first and rate-limiting step in reverse cholesterol
transport. Recently, strategies to measure cholesterol ef-
flux capacity of apolipoprotein B-depleted plasma have
been successfully used in clinical studies, revealing in-
verse correlations between cholesterol efflux capacity
and prevalent coronary artery disease, even stronger
than HDL-C levels [7, 8]. Indeed, the levels of circulating
HDL-C do not strictly reflect the cholesterol molecules
released from the macrophage foam cells typical of ath-
erosclerotic lesions, neither do they exert any of the
anti-atherogenic activities of HDL [9]. Thus, further un-
derstanding of the factors affecting cholesterol efflux
might reveal a higher atheroprotective potential than
HDL-C targeting agents.
The upstream stimulatory factor 1 (USF1) was origin-
ally associated with familial combined hyperlipidemia
[10] with subsequent associations with lipid levels [11]
[12, 13], coronary atherosclerosis [14], and acute cardio-
vascular events [15]. We recently showed that inactiva-
tion of USF1 in mice protects against atherosclerosis,
insulin resistance, obesity, and hepatic steatosis [16].
The beneficial metabolic phenotype of this mouse model
was linked to increased whole-body energy expenditure
and brown adipose tissue activity. Furthermore, Usf1 de-
ficiency corrected diet-induced dyslipidemia in mice,
manifested by reduced triglycerides and elevated levels
of HDL-C. The atheroprotective role of USF1 deficiency
was also observed in humans, in whom individuals hav-
ing a USF1 mRNA expression reducing allele displayed
elevated HDL-C and reduced triglyceride levels, as well
as reduced atherosclerosis in coronary arteries, also fea-
turing fewer calcified plaques [16]. However, whether
the elevated HDL-C was associated with an improved
functionality of HDL particles was not addressed in the
previous study. We now investigate whether USF1 af-
fects pathways involved in macrophage cholesterol accu-
mulation, with particular focus on cholesterol efflux, the
rate-limiting step in reverse cholesterol transport, and
whether the elevated HDL-C of Usf1 deficient animals




We use a congenic strain in C57Bl/6JRccHsd back-
ground in our studies with littermate controls. All ani-
mal procedures were reviewed and approved by the local
animal care committee and local government authorities.
The generation of Usf1 deficient mice has been previ-
ously described [16].
Isolation and composition of mouse HDL
HDL was isolated from pooled mice serum samples by
sequential ultracentrifugation using Table-Top ultracen-
trifuge (Beckmann Optima TL, USA) and KBr for dens-
ity adjustment. Serum samples were first adjusted to the
density (d) of 1.019 g/mL and the centrifuge tube filled
with a d = 1.019 g/mL KBr solution to the total volume
of 3 mL. The samples were centrifuged at + 5 °C for 2 h
at relative centrifugal field 500,000 x G. After centrifuga-
tion very low and intermediate density lipoproteins
(VLDL and IDL) were recovered in the top 1 mL frac-
tion and the bottom was adjusted to the density of
1.063 g/mL using solid KBr, filled to 3 mL with d = 1.063
g/mL KBr solution and centrifuged (+ 5 °C, 3 h, 500,000
x G). The top 1 mL fraction contained low density lipo-
proteins (LDL). To get the total mouse HDL fraction the
LDL infranatant fraction was adjusted with solid KBr to
the density of 1.21 g/mL, the vials filled with KBr 1.21 g/
mL density solution and then centrifuged (+ 5 °C, 18 h,
500,000 x G). Total HDL was obtained in top 1mL fraction.
The isolated HDL was dialyzed against phosphate-buffered
saline (PBS, pH 7.4) and stored at + 4 °C before analysis.
Isolated HDL was analyzed for lipids and APOA1 using the
methods described below.
Analysis of lipid and apoA-I concentration
Isolated HDL particles were analyzed for total choles-
terol (CHOD-PAP 1489232 kit; Roche Diagnostics
GmbH), choline-containing phospholipids (990–54,009;
Wako Chemicals GmbH) and triglycerides (GPO-PAP
1488872 kit; Roche Diagnostics GmbH) using fully en-
zymatic methods. Mouse apolipoprotein A-I (apoA-I)
was quantified by a sandwich enzyme-linked immuno-
sorbent assay (ELISA) as described [17].
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Gene expression analysis from USF1 silenced peritoneal
macrophages
RNA was extracted using the RNeasy Mini Kit (Qiagen)
according to manufacturer’s instructions. Quality of
RNA was analyzed using the Bioanalyzer platform
(Agilent Technologies). Two micrograms of total RNA
were treated according to standard Affymetrix eukaryotic
RNA labeling protocols (Affymetrix, Santa Clara, CA).
Fifteen micrograms of biotin labeled cRNA was fragmen-
ted according to Affymetrix eukaryotic sample protocol.
Hybridization, staining, and washing of the Affymetrix
HG-U133_Plus_2 Arrays were performed using the Affy-
metrix Fluidics Station 450 and Hybridization Oven 640
under standard conditions. The raw data were processed
using the GCRMA-normalization method [18].
Cholesterol accumulation in mouse peritoneal macrophages
Mouse peritoneal macrophages were collected from 8
weeks old female mice. Mice were pretreated 4 days with
500 μL thioglycollate (BD, BLL™ Thioglycollate Medium
Brewer Modified). Macrophages were collected in 1%
BSA in PBS and cultured in D-MEM (Sigma) supple-
mented with 20% FBS and 1% penicillin/streptomycin.
Cells were cultured for 4 days before experimentation to
remove the thioglycollate induced inflammation. For
cholesterol loading peritoneal macrophages were incu-
bated with acetylated LDL for 16 h. Some samples were
pre-treated with 10 ng/mL of LPS (Salmonella Minne-
sota R595) for 24 h before loading. Lipids were extracted
from the cells with organic solvent using n-Hexane and
isopropanol, 3:2 (v/v). After evaporation of the organic
solvent under nitrogen the residual lipids were dissolved
in methanol. Total cholesterol was measured with com-
mercial kit (CHOD-PAP # 1489232, Roche Diagnostics
GmbH, Mannheim, Germany). Remaining cells after
lipid isolation were collected and total protein was mea-
sured for adjustment of the final results.
In vitro experiments
Silencing of USF1 in vitro
The most effective USF1 silencing shRNA was screened
in immortalized human hepatocytes (IHH). IHH were
grown in William’s E medium (GIBCO-Life Technolo-
gies, Carlsbad, CA) containing 10% fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/
mL streptomycin, 100 nM (20mU/mL) insulin, and 50
nM dexamethasone (Sigma-Aldrich, St. Louis, MO) on
CellBIND® Surface cell culture plates (Corning, Corning,
NY). The human monocytic cell line, THP-1 and human
hepatocellular carcinoma cell line, HuH-7 were cultured
in RPMI (THP-1) or DMEM (HuH-7) medium supple-
mented with 10% fetal bovine serum and penicillin/
streptomycin and to THP-1 media 25 mM HEPES was
added. For transduction, 20,000 THP-1 cells seeded on
24-well plates or ~ 80% confluent HuH-7 cells in 12-well
plates were treated for 24 h with SIGMA MISSION len-
tiviral preparations containing either the control shRNA
expression vector (MISSION® pLKO.1-puro Non-Target
shRNA) or the USF1 silencing shRNA expression vector
(233475) at a MOI of ~ 1. Cells were selected with 6 μg/
mL of puromycin for 14 days and were then used for
cholesterol efflux assays.
Cell lines were found to be free of Mycoplasma
contamination.
Cholesterol efflux from THP-1 macrophages
THP-1 human monocytes (ATCC, Manassas, VA) were
grown at 37 °C in suspension culture in RPMI 1640
medium supplemented with 10% FBS, 25 mM HEPES,
and 1% penicillin/streptomycin. Differentiation into
macrophages was performed using 100 nM phorbol myr-
istate acetate (PMA, Sigma) for 3 days. After this the dif-
ferentiated macrophages were washed twice with PBS
and loaded by incubation in the presence of [3H]cholesteryl
oleate-labeled acetyl-LDL (25 μg of protein/well) in RPMI
1640 supplemented with 5% (v/v) lipoprotein-deficient
serum, 10mM HEPES, pH 7.4, and penicillin/streptomycin
for 48 h and without PMA. The cholesterol-loaded macro-
phage cells were then washed with PBS, and 2% serum or
HDL (as determined by 25 μg/mL HDL protein) derived
from either Usf1−/− or Usf1+/+ mice were added as choles-
terol acceptors. After 24 h incubation, the growth medium
was collected, and radioactivity was determined by liquid
scintillation counting. The cell layer was washed with PBS,
followed by addition of 0.2M NaOH to lyse the cells and
further incubated for 24 h at + 4 °C, after which the radio-
activity was assessed. Wells incubated without added accep-
tors were used as controls. Cholesterol efflux is expressed
as dpm in medium divided by the cell protein content (unit
used for the efflux: dpm/μg cell protein).
Western blot analysis of ABCA1
Cells were lysed on ice with buffer (10 mM HEPES, 150
mM NaCl, 0,5 mM MgCl2, 10% Glycerol, 0,5% Triton
X-100, 0,5% deoxycholate, pH 7.4) containing protease
inhibitors. Protein concentrations were determined, and
equal amount of proteins were loaded on 4–12%
SDS-PAGE gel (Bio-RAD) in sample buffer containing
β-mercaptoethanol without heating. After electrophor-
esis the separated proteins in gel were electro-trans-
ferred to nitrocellulose membrane. Membrane was
blocked with 5% milk TBS-T for 1 h and after washing
immunostaining was performed with primary antibody
(ABCA1, Bio-RAD and β-actin, Abcam), washed and
followed by incubation with Chemiluminence (Daco)
and IRDye 680RD (LI-COR) secondary antibodies. Im-
munoreactive proteins were detected with Super Signal
West Femto Maxium Sensitivity Substrate (ThermoFisher
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Scientific) using chemiluminesence and infrared imaging
system (LI-COR). Result were calculated with Image
Studio Lite program and the ABCA1 signal was adjusted
to β-actin.
Cholesterol esterification measurements
USF-1-silenced and control THP-1 macrophages were
incubated with or without acetylated LDL (acLDL,
50 μg/ml) in serum-free media for 24 h. Cells were
washed 3 times with PBS and incubated with [3H]-oleic
acid-BSA complexes in the serum-free medium for 2 h,
washed 3 times with PBS, and lipids were extracted with
hexane/isopropanol (3:2, v/v). Samples of the cell sus-
pensions were taken for protein determination and from
the extracted lipids [3H]-oleate incorporation into cho-
lesteryl esters was analyzed using thin layer chromatog-
raphy (TLC). The extracted lipids were separated by
TLC in n-heptane/isopropyl ether/glacial acetic acid/
methanol (60:40:4:2, vol/vol). Spots corresponding to
cholesteryl esters (CE) were scraped, the radioactivity
measured by scintillation counting and the CE counts
per total cell protein calculated.
For measuring the distribution of [14C]-cholesterol be-
tween unesterified cholesterol (C) and CE USF-1-si-
lenced and control THP-1 macrophages were incubated
with [14C]-cholesterol (1 μCi/ml) in serum-free media
for 24 h, washed with PBS and chased in serum-free
medium for 18 h. Lipids were extracted and separated by
TLC in n-hexane/diethyl ether/glacial acetic acid/water
(65:15:1:0.25, vol/vol). Spots corresponding to C and CE
were scraped, the radioactivity measured by scintillation
counting, and the [14C]-CE/total [14C]-cholesterol and
[14C]-CE/total cell protein ratios were calculated.
Results
As previously shown, the Usf1−/− mice displayed ele-
vated levels of plasma total cholesterol and phospho-
lipids [16]. Using fast protein liquid chromatography, we
established that cholesterol and phospholipid concentra-
tions were elevated in the HDL fractions of Usf1−/− mice
as compared Usf1+/+ mice [16]. In the present study, we
first investigated whether USF1 inactivation in human
macrophages affects cholesterol efflux from macrophage
foam cells. We silenced USF1 in THP-1 macrophages
using shRNA, achieving 79% silencing, and observed sig-
nificant increase in cholesterol efflux capacity from these
cells (Fig. 1a). This could be mediated by ABCA1, whose
mRNA expression was upregulated by about 3.2-fold in
the THP-1 cells subjected to USF1 knock-down (Fig. 1b)
whereas the expression of ABCG1 was downregulated
(52%), and that of SCARB1 (commonly known as SR-BI)
remained unaltered. In Western blot analyses, consistent
with higher ABCA1 transcript abundance, ABCA1 dis-
played a trend of increase in USF1 silenced THP-1
macrophages (Fig. 1c). Interestingly, we also detected a
significant increase of ABCA1 protein in human hepa-
toma cells subjected to USF1 knock-down (HuH7;
Fig. 1d). Since USF1 has previously been identified
as a repressor of ABCA1 [19], our results suggest
that USF1 inactivation could boost both cholesterol
efflux capacity of macrophages as well as enhance nascent
HDL particle secretion from the liver, contributing to the
HDL elevation observed in Usf1−/− mice [16].
In addition to studying the impact of USF1 on the key
cholesterol transporters, we also studied its effects on
cholesterol acceptors. Serum derived from Usf1−/− mice
displayed enhanced capacity to induce cholesterol efflux
from THP-1 foam cells as compared to Usf1+/+ serum
(Fig. 2a). Interestingly, when the experiment was re-
peated with HDL isolated from mouse sera, the acceptor
capacity of Usf1−/− derived HDL was superior to that of
Usf1+/+ HDL (Fig. 2b), explaining the enhanced serum
facilitated removal of cholesterol from macrophage foam
cells. Thus, both enhanced cholesterol transporter ex-
pression and cholesterol acceptor functionality appear to
boost the first step of macrophage-specific reverse chol-
esterol transport in conditions of USF1 deficiency.
Elevated levels of HDL-C are associated with improved
HDL lipid composition in humans [20, 21], and in-
creased HDL phospholipid content has been reported to
confer better cholesterol acceptor properties to HDL
particles [22, 23]. We next studied whether HDL com-
position accounts for the higher cholesterol efflux effi-
ciency resulting from USF1 inactivation. The HDL
particles derived from Usf1−/− mice were enriched in
phospholipids and cholesterol while the proportional
amount of apolipoprotein A1 (APOA1) was decreased
(Fig. 2c), indicating a higher phospholipid/APOA1 mass
ratio in HDL. The higher proportion of phospholipids
(PL) provides a plausible explanation to the elevated
cholesterol acceptor capacity of Usf1−/− derived HDL
particles. Importantly, the concentrations of phospho-
lipids, cholesterol, and APOA1 were elevated in the
HDL fraction derived from Usf1−/− mice (Fig. 2d).
Together, these findings explain the functional super-
iority of Usf1−/− HDL and serum as acceptors in
cholesterol efflux.
Because increased uptake of modified LDL by macro-
phages promotes the generation of cholesterol-loaded
foam cells [24], an early sign of atherosclerosis, we next
examined whether expression of USF1 has an effect on
cholesterol accumulation in macrophages. For this aim,
we measured the content of cholesterol in peritoneal
macrophages from Usf1+/+ and Usf1−/− mice after incu-
bation of the cells with acetylated LDL in the absence
or presence of lipopolysaccharide (LPS), a potent proin-
flammatory activator of macrophages. We found that
while in the absence of LPS there was no difference, in
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the presence of LPS the cholesterol accumulation in-
duced by acLDL was 48% lower in Usf1 deficient mac-
rophages as compared to wild type cells (Fig. 3a). Usf1
deficiency thus confers resistance to LPS-induced pro-
inflammatory response in macrophages. The reduced
proinflammatory response in Usf1 deficient macro-
phages was also reflected by lower mRNA expression of
NF-κB, including both Nfkb1 and Nfkb2 (Fig. 3b). Fur-
thermore, secretion of pro-inflammatory cytokines
MCP-1 (Fig. 3c) and IL-1β (Fig. 3d) was significantly re-
duced in USF1-silenced THP-1 macrophages when
compared to control cells, demonstrating the presence
of a cell-autonomous component of the anti-
inflammatory effect of USF1 deficiency.
Modified LDL is taken up by several types of scavenger
receptors, of which SR-A1 (gene name MSR1) and CD36
are responsible for > 75% of its internalization [25].
SR-A1 (MSR1) mRNA expression was downregulated by
4.2-fold in USF1 silenced THP-1 macrophages (Fig. 3e),
likely explaining the relative resistance conferred by
USF1 deficiency to cholesterol accumulation in macro-
phages observed upon the inflammation-mimicking
conditions (LPS exposure). In contrast, the mRNA ex-
pression of CD36 was upregulated by 1.7-fold (Fig. 3e).
a b
c d
Fig. 1 Inactivation of USF1 enhances cholesterol efflux. a) Cholesterol efflux from THP-1 macrophages treated with non-targeting (NT) and USF1
silencing lentivirus (shUSF1) to wild-type mouse serum, n=6 per condition from two independent experiments. (b) Gene expression of cholesterol
transporters relevant for cholesterol efflux in THP-1 macrophages. n=3-4. (c) ABCA1 protein expression in THP-1 cells. n=6/6 from two independent
experiments. (d) ABCA1 protein expression in HuH7 hepatoma cells. n=6/6 from two independent experiments. Molecular weights of 220Kda for
ABCA1 and 42 kDa for β-actin are depicted in Panels c and d. *** P < 0.001, ** P < 0.01, * P < 0.05, for comparisons between groups
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Taken together, by both reducing cholesterol accumula-
tion and enhancing cholesterol efflux, USF1 deficiency
prevents cholesterol accumulation in macrophages, thus
attenuating foam cell formation.
As macrophage cholesterol efflux is determined not only
by the quantity and quality of cholesterol acceptors and
transmembrane transporters, but also by the function of
intracellular lipid-regulatory enzymes, we next investi-
gated the effect of USF1 on intracellular enzymes affecting
cholesterol efflux. Lysosomal acid lipase (LAL; gene name
Lipa) is an enzyme responsible for hydrolysis of choles-
terol esters. LIPA has been reported to contribute to chol-
esterol efflux [26], and overexpression of Lipa has been
shown to prevent atherogenesis [27, 28]. ACAT1
re-esterifies free cholesterol generated by LIPA to produce
cytoplasmic cholesterol ester droplets, and its deficiency
results in decreased cholesterol efflux from macrophages
[29]. Neutral cholesterol ester hydrolase 1 (Nceh1), located
on the cholesterol ester droplets, mediates their hydrolysis
in both murine and human macrophages [30], and abla-
tion of Nceh1 accelerates atherosclerosis [31]. To study
these intracellular pathways regulating cholesterol efflux,
we conducted genome-wide expression array analysis of
peritoneal macrophages isolated from Usf1+/+ and Usf1−/−
mice. This analysis demonstrated that in the USF1 defi-
cient macrophages the expression of Lipa was upregulated
by 63%, Acat1 by 23%, and Nceh1 by 41% (Fig. 4a). In
addition, in THP-1 macrophages similar increases in ex-
pression upon USF1 silencing were observed for both
NCEH1 and LIPA, but not for ACAT1 (Fig. 4b). In func-
tional analysis, however, measurement of macrophage
cholesterol esterification by a radiometric assay showed
no significant difference between USF1 silenced (14,805 ±
1266 dpm/mg protein) and control THP-1 macrophage
cells (12,500 ± 2327 dpm/mg protein). We further ana-
lyzed the impact of USF1 silencing on the distribution of
a b
c d
Fig. 2 USF1 deficiency improves acceptor capacity of serum and HDL particles, enriched with phospholipids (PL). (a) Cholesterol efflux from THP-
1 macrophages to serum derived from Usf1+/+ and Usf1-/- mice. n=5 for each column. Serum samples from five individual Usf1+/+ and Usf1-/-
mice were analyzed in two independent experiments. (b) Cholesterol efflux from THP-1 macrophages to HDL particles derived from Usf1+/+
(n=7 mice, pooled HDL) and Usf1-/- mice (n=8 mice, pooled HDL), n=6 parallel wells for THP-1 cells in two independent experiments. (c) Mass
composition (%) of HDL particles isolated from Usf1+/+ and Usf1-/- mice. n=11/9. (d) HDL particle content (mmol/L for lipid and g/L for APOA1),
n=11/9. *** P < 0.001, ** P < 0.01, * P < 0.05, for comparisons between groups
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[14]-cholesterol between unesterified and esterified intra-
cellular pools in the THP-1 macrophages in the absence
and presence of acLDL loading. These experiments
revealed no significant difference in the [14C]CE/total C
ratio (no acLDL loading: shNT, 0.0549 ± 0.0135 cpm/cpm;
shUSF1, 0.0676 ± 0.0316 cpm/cpm, and acLDL loading:
shNT, 0.3641 ± 0.0464 cpm/cpm; shUSF1, 0.4374 ± 0.0108
cpm/cpm) or in the [14C]CE/total protein ratio (no acLDL
loading: shNT, 3.508 ± 0.424 cpm/μg protein; shUSF1,
4.047 ± 0.225 cpm/μg protein, and acLDL loading; shNT,
22.801 ± 7.906 cpm/μg protein; shUSF1, 27.215 ± 3.508
cpm/μg protein). Although we did not observe differences
in the ACAT-mediated cholesterol esterification or the
distribution of [14C[−cholesterol, the enhanced choles-
terol efflux and the elevated expression of ABCA1
mRNA and protein, as well as the altered mRNAs ex-
pression of LIPA and NCEH1 imply that the effects of
Usf1 deficiency extend to inducing modulation of intra-
cellular cholesterol pathways which also contribute to the





Fig. 3 USF1 deficiency attenuates LPS-induced proinflammatory responses of macrophages and protects against inflammation-induced
cholesterol accumulation. (a) Cholesterol content of mouse peritoneal macrophages incubated without or with LPS. n=4/5/9/8 parallel wells in
two independent experiments. (b) Expression of Nfkb1 and Nfkb2 (NF-κB) in peritoneal macrophages in the absence of LPS. n=4/4. (c) Secretion
of MCP-1 from THP-1 macrophages +/- acLDL, n=6 from 2 independent experiments. (d) Secretion of IL-1β from THP-1 macrophages +/- acLDL,
n=6 from 2 independent experiments. (e) Gene expression of cholesterol transporters relevant for cholesterol uptake in THP-1 macrophages in
the absence of LPS. n=4 in each column. *** P < 0.001, ** P < 0.01, * P < 0.05, for comparisons between groups
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Discussion
In this study we have identified USF1 as a novel factor
affecting HDL functionality, thus having an impact on
HDL metabolism beyond its effects on the levels of
HDL-C. The majority of epidemiological studies of HDL
functionality have recently focused on macrophage chol-
esterol efflux [7, 8]. These studies have shown that chol-
esterol efflux is inversely proportional to CVD risk, and
demonstrated cholesterol efflux to be a better CVD risk
predictor than HDL-C levels. Thus, cholesterol efflux fa-
cilitated by HDL merits further study, and factors boosting
cholesterol efflux could potentially provide antiatherogenic
effects. Based on our study, USF1 appears to be such factor,
regulating the cholesterol acceptor properties of HDL parti-
cles, such their phospholipid (PL) content. Moreover, we
show evidence that USF1 modulates the expression of chol-
esterol transporters (SR-A1, ABCA1), and gene expression
of critical metabolic pathways of intracellular cholesterol
ester hydrolyzing and esterifying enzymes crucial for the
intracellular cholesterol turnover in macrophages. These
observations are summarized in Fig. 5 and discussed below.
First, USF1 silencing activated cholesterol removal
from macrophages. This enhancement in cholesterol
release capacity was most likely due to enhanced
ABCA1-mediated cholesterol efflux. The results agree
well with previous studies in which USF1 was identified
as a repressor of ABCA1 [19, 32]. The expression of
SCARB1, a passive transporter, was unchanged, while
the mRNA level of ABCG1 was decreased. It is possible
that ABCG1 expression could be reduced in response to
the change in cholesterol status of the cells, as ABCA1
expression has been increased by a mechanism that may
not affect ABCG1. This finding requires further study.
The observations suggest that upon USF1 deficiency,
ABCA1 mediated cholesterol efflux is the major pathway
responsible for net macrophage cholesterol efflux. As
ABCA1 protein was increased in USF1 silenced hepato-
cytes, USF1 deficiency could also contribute to elevated
plasma HDL-C levels by enhancing secretion of nascent
HDL particles from the liver.
Second, USF1 deficiency improved macrophage chol-
esterol efflux also through conferring enhanced choles-
terol acceptor capacity to serum and HDL particles. The
Usf1−/−-derived HDL particles exhibited higher phospho-
lipid content than those of Usf1+/+ mice, and since Four-
nier et al. have previously shown that HDL phospholipid
content is the major factor determining HDL-dependent
cholesterol efflux [22], our results point to elevated
phospholipid content being one important factor respon-
sible for the enhanced acceptor capacity of Usf1−/−-de-
rived HDL particles (Fig. 5).
Third, USF1 deficiency increased the gene expression
of intracellular enzymes affecting macrophage choles-
terol metabolism. Of these enzymes, LIPA and NCEH1
are responsible for cholesterol ester hydrolysis, releasing
unesterified cholesterol and fatty acids, and ACAT1 for
re-esterification of cholesterol. High levels of NCEH1
and LIPA have been shown to protect against athero-
sclerosis [28, 31], and they are associated with increased
cholesterol efflux [27, 30]. The upregulation of these
a b
Fig. 4 Intracellular cholesterol pathways are upregulated upon USF1 deficiency. (a) Lipa, Acat1 and Nceh1 mRNA expression in mouse peritoneal
macrophages. n=5/5 (individual animals). (b) LIPA, ACAT1 and NCEH1 mRNA expression in THP-1 macrophages. n=4/3; for NCEH n=3 per group.
** P < 0.01, * P < 0.05, for comparisons between groups
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mRNAs potentially indicates a higher rate of cholesterol
trafficking in the cell, resulting in enhanced cellular
cholesterol transfer to acceptors (Fig. 5). However, in
radiolabeling experiments, we did not observe a signifi-
cant difference in cholesterol esterification or [14C]-chol-
esterol distribution between unesterified and esterified
pools between USF1 deficient and control cells. This is
consistent with a model in which the intracellular turn-
over of cholesterol in USF1 deficient cells is enhanced,
making it more readily available for ABCA1-mediated
efflux to HDL acceptors (Fig. 5).
Usf1 deficiency protected against LPS-induced in-
crease in cholesterol deposition into macrophages. LPS
has been implicated in human cardiovascular disease
[33], and is thought to contribute to the development of
arterial plaques through activation of pro-inflammatory
pathways [34]. The chronic low-grade inflammation as-
sociated with dyslipidemia predisposes to atherosclerosis
via the formation of foam cells. Thus, the atheroprotec-
tive effect of Usf1 deficiency in Ldlr−/− background [16]
could be partly mediated by the attenuated formation of
foam cells despite the severe hyperlipidemia observed in
Ldlr−/− background. The reduced cholesterol accumula-
tion in the present study is likely explained by the reduc-
tion in scavenger receptor SR-A1 (gene MSR1) whose
mRNA expression was decreased following USF1 deple-
tion. On the other hand, the mRNA expression of CD36,
another scavenger receptor, was elevated. While this
finding may first seem contradictory, it appears more
plausible considering that CD36 is a marker of
anti-inflammatory M2 macrophages [35]. In fact, as the
expression of NF-κB was down-regulated in USF1 defi-
cient macrophages as well as the secretion of
pro-inflammatory cytokines MCP-1 and IL-1β, increased
CD36 expression is well in line with the general
anti-inflammatory status conferred by Usf1 deficiency
Fig. 5 Schematic presentation of the proposed mechanism for the effects of USF1 deficiency on cholesterol flux through a macrophage foam
cell. Uptake of cholesteryl esters (CE) present in the core of modified LDL particles promotes the generation of macrophage foam cells. Modified
LDL is taken up by scavenger receptors, such as SR-A1. Lack of USF1 resulted in reduced mRNA levels of SR-A1 and attenuated LPS-induced
macrophage cholesterol deposition. Intracellular cholesterol flux-regulating enzymes, lysosomal acid lipase (LAL, gene name LIPA), acetyl-CoA
cholesterol acyltransferase 1 (ACAT1) and neutral cholesterol ester hydrolase 1 (nCEH1) are key factors modulating macrophage cholesterol
metabolism. Deficiency of Usf1 caused an upregulation in expression of NCEH1 and LIPA in both mouse peritoneal macrophages and human
THP-1 cells, thereby enhancing intracellular cholesterol flux from lysosomes via CE droplets to plasma membrane. The protein expression of
ABCA1, an important cholesterol transporter on macrophage plasma membrane, was also increased due to lack of USF1, further accelerating the
removal of cholesterol to cholesterol acceptors (HDL), whose plasma levels were elevated in Usf1 deficient mice (16). The HDL particles derived
from Usf1-/- mice had a higher proportion of phospholipids (PL) in HDL further explaining the elevated cholesterol acceptor capacity of Usf1-/-
derived HDL particles. ABCA1 protein levels were upregulated in USF1 deficient hepatocytes, which may partially explain the elevated HDL levels
in USF1 deficient mice. Expression of NF-κB, a key regulator of inflammation was decreased in peritoneal macrophages from USF1 deficient mice
and, furthermore, secretion of cytokines (MCP-1 and IL-1β) was found to be decreased in USF1 silenced THP-1 macrophages. Arrows denote the
effects of USF1 deficiency at relevant sites
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[16]. The anti-inflammatory environment most likely re-
pels cholesterol accumulation into macrophages.
This study, showing that Usf1 deficiency enhances
cholesterol efflux, lowers macrophage inflammatory sta-
tus, and reduces cholesterol accumulation, supports and
expands our previous findings, in which we showed that
Usf1 deficiency results in higher HDL-C, lower triglycer-
ides, and protection against diet-induced obesity, insulin
resistance, systemic inflammation, and atherosclerosis
[16]. Mice lacking Usf1 on Ldlr−/− background displayed
a 4-fold reduction in atherosclerosis, and human individ-
uals harboring an allele associated with 18% reduction in
USF1 mRNA displayed a 45% reduction in plaque area
in coronary arteries as well as 47% reduction in plaque
calcification. While the causal relationship between ele-
vated cholesterol efflux and CVD events remains to be
proven in future studies, our study is well in line with
epidemiological reports showing enhanced cholesterol
efflux capacity to be associated with reduction in CVD
events [7], and provides further support for the import-
ance of functional improvement of HDL particles re-
garding atheroprotection. The present study includes
some important limitations: It is possible that USF1 reg-
ulates macrophage polarization between M1 and M2,
which could affect the results. Further, although we re-
port an elevated total phospholipid content in HDL de-
rived from Usf1 deficient mice, the mechanism behind
this observation remains unknown. Finally, thorough
HDL phospholipidomics and proteomics analyses would
be relevant in order to address in more detail the impact
of Usf1 deficiency on HDL function in cholesterol efflux.
These issues are important goals for the future studies.
Conclusions
We have identified USF1 as a novel factor affecting
macrophage inflammatory status and cholesterol homeo-
stasis, whose deficiency not only raises HDL-C levels,
but, more importantly, improves HDL functionality and
reduces inflammation.
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